Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Filings indexed 767 across all filing types
Latest filing 2024-06-27 Report Publication Anno…
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Publication of Annual Report
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. titled 'Publication of Annual Report'. It explicitly states that the company has published its Annual Report and provides a link to the company's website to view it. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore falls under the Report Publication Announcement (RPA) category.
2024-06-27 English
Director's Dealing 2024
Director's Dealing
2024-06-24 English
Regulatory Filings 2024
Regulatory Filings
2024-06-20 English
Grant of Options and Restricted Stock Units
Director's Dealing Classification · 1% confidence The document is a formal notification of share-based compensation (options and restricted stock units) granted to Persons Discharging Managerial Responsibilities (PDMRs), specifically non-executive directors. It includes the standard regulatory disclosure table required for such transactions, detailing the nature of the transaction, the individuals involved, and the volume/price of the instruments. This falls squarely under the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions or equity grants by company directors and executives.
2024-06-14 English
Director's Dealing 2024
Director's Dealing
2024-06-13 English
Director's Dealing 2024
Director's Dealing
2024-06-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.